Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CYP3A5 Antibodies:
anti-Cow (Bovine) CYP3A5 Antibodies:
anti-Mouse (Murine) CYP3A5 Antibodies:
Go to our pre-filtered search.
The CYP3A5 genotype had no impact on the concentrations of cyclosporine A and tacrolimus at any investigated time point
We confirmed CYP3A5 metabolic activity with the CYP3A4 (show CYP3A4 Antibodies) selective inhibitor CYP3CIDE.
Part of the differences in tacrolimus pharmacokinetics and transplantation outcomes may relate to differences between populations in the genetics of tacrolimus-metabolizing enzymes. The best-known example is the allelic frequency of the loss-of-function CYP3A5*3 allele.
conclude, therefore, that there is either no association between CYP3A5 expression and blood pressure or, if there is a relationship, the strength of the association is very small in Ghanaian population.
The alleles CYP3A5*3 and CYP3A4 (show CYP3A4 Antibodies)*18B were significantly associated with dose-adjusted tacrolimus blood trough concentrations and had a strong time-genotype interaction with tacrolimus pharmacokinetics.
MDR1 (show TBC1D9 Antibodies) and CYP3A5 genetic polymorphisms significantly influence plasma trough levels and therapeutic response of imatinib in patients with chronic myeloid leukemia (show BCL11A Antibodies). Patients with GG genotype for CYP3A5-A6986G (P=0.016) and TT genotype for MDR1 (show TBC1D9 Antibodies)-C3435T (P=0.013) polymorphisms had significantly higher trough levels of imatinib.
The CYP3A5 gene may be associated with the risk of hypertension in the Chinese Han population, and this effect may be exacerbated by drinking.
The study demonstrated no correlation between CYP3A5 genotype and the development of vincristine neurotoxicity in childhood malignancies.
The A/G genotypes, G/G genotypes, and G allele of CYP3A5*3 in the LEDVT group were observed with increased frequency compared with the control group. The genotype distributions of the CYP2C9 (show CYP2C9 Antibodies)*3, CYP2D6 (show CYP2D6 Antibodies)*10, and CYP3A5*3 genetic polymorphisms were associated with the warfarin maintenance dose.
Steroid resistance during acute renal allograft rejection is associated with donor genotype and intragraft expression levels of CYP3A5.
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase